04:39 AM EST, 01/10/2025 (MT Newswires) -- Innate Pharma ( IPHA ) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases.

The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma.

Additionally, Innate said it is advancing its Antibody-Drug Conjugate programs, with lead candidate IPH4502 in a phase 1 trial for advanced solid tumors.

Innate is also seeking a partner for lacutamab in T-cell lymphomas and collaborating with AstraZeneca ( AZN ) on monalizumab, which is in a phase 3 trial for non-small cell lung cancer.